Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023418 (leukemia)
 93,477 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The cooperative group included 18 provincial and district hospitals. A retrospective study was carried out on 140 cases of therapy related leukemia (TRL) caused by bimolane (BML) for psoriasis from 1984 to 1992. This series of BML-TRL consists of 90 male and 50 female patients. 87.1% of them were from 20 to 50 years old. Annual incidence varied from 4 to 24 cases, and was maintained at this level through the period from 1986 to 1991 without any declining tendency. The average time interval between BML administration and diagnosis of leukemia was 46 months. 138 cases were diagnosed as ANLL and 2 cases were suspected of having ALL. Subtype frequency was shown as follows: M3 > M2 > M5 > M4 > M1 > M6. 67.1% of the patients had a low peripheral white blood cell counts (< 5 x 10(9)/L). 116 patients received chemotherapy. A 26.7% remission rate was obtained with 18.1% complete remission and 8.6% partial remission. A 115 day median survival was calculated through a follow up survey of 95 patients. Finally, we concluded that: (1) This has been the largest group of non-cancer-therapy-related-leukemia patients ever reported. This type of leukemia is characterized by a shorter latent period, higher remission rate less incidence of myelodysplastic syndrome and more frequent occurrence of leukopenia, as compared with other types of TRL. BML is supposed to be a strong leukemia-causing cytotoxic agent. Use of this drug in psoriasis and other benign diseases is not recommended.
Zhonghua Nei Ke Za Zhi 1993 Oct
PMID:[140 cases of acute leukemia caused by bimolane]. 815 36

Ten cases of acute myeloperoxidase-negative myeloid leukaemia (AML) were reported. They had no typical mopholocid negative for lymphocic features and were negative antigens. However 5 cases were positive for NSE/NaF stain. 9 of the 10 cases expressed more than one myeloid antigens. The authors are of the opinion that it is very difficult to diagnose myeloperoxidase-negative AML and combination of cytochemical and immunological techniques is recommended in this respect.
Zhonghua Nei Ke Za Zhi 1993 Mar
PMID:[Characterization of morphologic, cytochemical and immunological features in myeloperoxidase negative acute myeloid leukaemia]. 815 51

In order to clarify the role of interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF alpha) in the pathogenesis of acute leukemia, IL-6 and TNF alpha level was determined in patients with various types of acute leukemia. In comparison with normal subjects, IL-6 activity was significantly elevated in patients with ALL and ANLL (P < 0.01) and TNF alpha level increased in patients with ANLL (P < 0.05). The effect of IL-6 and TNF alpha on leukemia cell in vitro was also observed. The results indicated that IL-6 can promote the proliferation of leukemia cells, while TNF alpha can inhibit proliferation of leukemia cell in vitro. It is suggested that abnormal level of TNF alpha and IL-6 in patients with acute leukemia is probably related to the pathogenesis of acute leukemia.
Zhonghua Nei Ke Za Zhi 1993 Feb
PMID:[Tumor necrosis factor and interleukin 6 in acute leukemia]. 840 30

The method of reverse transcription coupled with polymerase chain reaction (RT-PCR) has been used to detect multidrug resistance gene MDR1 expression in 73 leukemia patients. Specificity of MDR1 PCR product was identified by a probe labelled with biotin. In this paper, beta 2M mRNA (a 120bp of PCR product) was selected as an internal control for semi-quantitative analysis of MDR1 mRNA (a 157bp of PCR product). Detection of MDR1 expression was positive in 31 of the 73 patients with leukemia. The percentage of MDR1+ and the value of MDR1/beta 2M in the relapsed acute leukemia and CML in blast crisis were 76.00% and 0.798 +/- 0.266, they were significantly higher than those in newly diagnosed acute leukemia (25.00% and 0.386 +/- 0.128) and complete remission leukemia (25.00% and 0.151 +/- 0.059), MDR1/beta 2M in newly diagnosed was significantly higher than that in complete remission. We found that MDR1 gene expression correlated well with response to chemotherapy in 53 cases of acute leukemia. The refractory rate in patients with MDR1+ was 75.00%, while it was 15.00% in MDR1- (P < 0.01). We thought that the determination of MDR1 expression level in acute leukemia could provide a valuble information for designing chemotherapeutic regimen in individual patient, and a high level of MDR1 expression correlated closely with drug resistance in clinical leukemia chemotherapy.
Zhonghua Nei Ke Za Zhi 1995 Jul
PMID:[Analysis of the multidrug resistance MDR1 gene expression in clinical leukemia with RT-PCR]. 855 28

HTLV-I causes T-cell leukemia and tropical spastic paraparesis (TSP) in a minority of infected people, whereas the majority remain healthy. The virus differs little in sequence between isolates but has been shown to have a quasispecies structure. Using the Nei and Gojobori algorithm, we have shown that the proportion of nonsynonymous to synonymous changes in HTLV-I proviral tax gene sequences from healthy seropositive subjects (Dn/Ds = 0.9 to 1.3) is significantly higher than those from TSP patients (Dn/Ds = 0.3 to 0.6). Here we show that the distinction between healthy seropositives and TSP patients can only be seen with proviral tax sequences, but not with cDNA, the amino-terminal or carboxy-terminal half of tax, or the rex gene. The Dn/Ds ratio of proviral tax sequences was used to analyze two TSP patients with atypical features and to investigate the influence of cytotoxic T cells (CTL) on the viral quasispecies.
 ...
PMID:Evolution in a chronic RNA virus infection: selection on HTLV-I tax protein differs between healthy carriers and patients with tropical spastic paraparesis. 864 14

The authors established a highly sensitive, specific and quantitative method-RT-PCR for measuring the levels of MDR1 mRNA in 91 acute leukemic samples (including 30 untreated cases, 32 remission cases, 29 refractory and relapse cases). The results showed that MDR1 mRNA positive rate for refractory and relapse cases, untreated cases and remission cases were 82.8%, 40.0%, 28.1% respectively. In untreated patients, it was found that the first complete remission rate differed significantly between MDR1 positive (41.7%) and MDR1 negative groups (88.9%) (P < 0.05). In remission group, MDR1 positive cases had a higher relapse rate than MDR1 negative case (66.7%; 13.0% P < 0.01) and all these cases relapsed of MDR1 gene overexpression (6 cases) were resistant to further treatment. It is concluded that the expression of MDR1 mRNA might be an unfavorable prognostic factor for patients with acute leukaemia and could predict the efficacy of intensive chemotherapy and serve as a high risk factor for early and resistant relapse.
Zhonghua Nei Ke Za Zhi 1995 Oct
PMID:[A clinical study on multidrug resistance gene (MDR1) expression in acute leukemia]. 873 23

Immunoglobulin heavy chain (IgH) gene rearrangement serves as a marker of clonality in B lymphoproliferative malignancies. In order to study the IgH rearranged gene in acute nonlymphoblastic leukemia (ANLL) patients we combine polymerase chain reaction (PCR) with Southern blot to detect 41 ANLL patients and 7 of them (17.1%) were found to have IgH rearrangement by PCR amplification. All these 7 positive cases were confirmed by Southern blot. The sensitivity of this method was 10(-4)-10(-5) level. In 12 patients with complete remission, 3 (25.0%) were found to have IgH rearranged gene. All these 3 cases had clinical relapse within 6 months. Our results show that IgH rearrangement not only may occur in lymphoblastic leukemia of B lineage, but also can be found in ANLL. The mechanism may be that in some ANLL patients, the leukemic transforming event might involve stem cells capable of both B cell and myeloid differentiation or ANLL might differentiate along different lineage with predominant appearance of one or the other subclone in the course of the disease.
Zhonghua Nei Ke Za Zhi 1996 Sep
PMID:[Detection of immunoglobulin heavy chain (IgH) gene rearrangement in ANLL by polymerase chain reaction amplification and Southern blot]. 959 50

Multidrug resistance (MDR) in leukemia and the reversal of MDR by cyclosporin A (CsA) in vitro have been studied through intracellular accumulation of daunorubicin (DNR) in leukemic myeloblasts. The study was carried out with real-time flow cytometry and relative expression levels of MDR, which is estimated by RNA in situ hybridization in 26 patients suffering from leukemia. The change of intracellular DNR accumulation in vitro after adding CsA was also analyzed. The results showed that intracellular DNR accumulation in newly diagnosed and treated patients (MDR1 negative) with remission increased significantly than that in refractory and relapsing patients (P < 0.01). Good reversal effect was obtained in refractory patients and MDR1 positive relapsing patients by adding CsA (P < 0.01). It is suggested that MDR detection by the two above-mentioned methods could help to project the chemotherapy schedule clinically, CsA had obvious reversal effect on the drug-resistant leukemic cells in vitro.
Zhonghua Nei Ke Za Zhi 1996 Sep
PMID:[Detection of multidrug resistance in patients with leukemia by using flow cytometry and RNA in situ hybridization]. 959 51

In order to study the cell origin of acute leukemia with lack of lineage specific antigen expression, the dynamic change of cell surface markers in 25 patients of acute leukemia unclassified with immunologic criteria were analysed by using APAAP immunoenzymatic method with monoclonal antibodies after chemotherapy or relapse. The results showed that 5 patients, whose leukemic cells expressed only CD38 antigen in the first visit, expressed T cell differentiated antigen after chemotherapy or relapse. 4 patients, who expressed B cell specific markers after chemotherapy or relapse, all expressed only CD9 antigen in the first visit. 4 of the 6 patients who expressed only HLA-DR antigen were found to have B cell markers on their leukemic cells surface after chemotherapy or relapse. One patient expressed B cell surface markers after chemotherapy and another expressed T cell surface markers after relapse, both of them expressed CD38 and HLA-DR antigens in the first visit. In 4 other patients whose leukemic cells were lacking of in any cell differentiated antigen expressing, one expressed B cell markers and another expressed T cell markers after chemotherapy. The change of cell surface markers showed the evolution and progression of leukemic cell clone. Dynamic study is useful to distinguish the cell origin of leukemia.
Zhonghua Nei Ke Za Zhi 1996 Sep
PMID:[Dynamic analysis of cell surface markers in acute leukemias unclassified with immunologic criteria]. 959 52

In order to investigate whether apoptosis occurs in vivo in patients with leukemia in different stage (before, during and after chemotherapy). We detect apoptosis of peripheral blood leukemia cells in 10 patients before, during and after chemotherapy with in situ TdT fluorescence measurement and DNA electrophoresis. The results showed that apoptotic cells were few (0-2.9%) before chemotherapy, increased obviously (11.4%-72.0%) during chemotherapy in patients with complete remission (CR) or partial remission (PR), but decreased (0-2.9%) after chemotherapy (10-14 days). Apoptotic cells were few (0-5.7%) during chemotherapy in four patients without remission. Therefore, only effective drug therapy could induce apoptosis. DNA ladder cannot be detected by agarose gel electrophoresis either before, during and after chemotherapy. So we considered that in situ TdT assay is possible to apoptosis in vivo in the early course of chemotherapy for immediate modification of chemotherapy, while electrophoretic analysis is not sensitive enough to detect apoptotic cells in vivo.
Zhonghua Nei Ke Za Zhi 1997 May
PMID:[A study on relationship between chemotherapy of acute leukemia and apoptosis in vivo]. 1037 69


<< Previous 1 2 3 4 Next >>